FRANKFURT (Reuters) – The European Union’s drug regulator this week will review a possible wider use of Novo Nordisk’s weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks.
The possible new indication, based on a drug trial known as SELECT, will be assessed this week during the monthly meeting of the watchdog’s committee for medicinal products for human use (CHMP), a meeting agenda posted on the watchdog’s website showed on Monday.
(Reporting by Ludwig Burger; editing by Jason Neely)
Comments